Has anybody been on the olaratumab trial?
The results of the phase Ib/II trial were presented at ASCO:
http://abstracts.asco.org/156/AbstView_156_147332.html
It's not clear whether they had any synovial sarcoma patient on the trial but the results look promising.
The next trial is phase 3 and is not recruiting yet but probably will start soon:
https://clinicaltrials.gov/ct2/show/NCT02451943
The phase 3 trial started recruiting in 126 locations...
A phase 1 trial of olaratumab as monotherapy:
Olaratumab is now getting a new name, Lartruvo and it looks like it will be made available very soon to European soft tissue sarcoma patients:
http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2016/09/news_detail_002602.jsp&mid=WC0b01ac058004d5c1
The FDA just granted accelerated approval to olaratumab which we should call lartruvo:
http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm525878.htm
Has anybody tried this drug?
This is an option for me if I pick it.
More details on Olaratumab in the following interview of several oncologists:
Mark Agulnik, MD; Brian Van Tine, MD, PhD; Richard F. Riedel, MD; and Victor Villalobos, MD, PhD, outline the FDA approval of olaratumab + doxorubicin and their effects on the treatment paradigm for soft tissue sarcoma.
They certainly make it sound very promising. I still would like to hear the experience of synovial sarcoma patients…
A few sarcoma experts explain how they decide which patient should get Olaratumab+Doxorubicin in this video:
Mark Agulnik, MD; Brian Van Tine, MD, PhD; Richard F. Riedel, MD; and Victor Villalobos, MD, PhD, outline the appropriate patients to use olaratumab in combination with doxorubicin as treatment for soft tissue sarcoma.
A few more interesting videos regarding Olaratumab:
Richard F. Riedel, MD, and Brian Van Tine, MD, PhD, discuss the toxicity profile of olaratumab and doxorubicin in patients with soft tissue sarcoma.
Victor Villalobos, MD, PhD; Brian Van Tine, MD, PhD; and Richard F. Riedel, MD, describe sequencing with olaratumab in patients with soft tissue sarcoma.
Brian Van Tine, MD, PhD; Victor Villalobos, MD, PhD; and Richard F. Riedel, MD, provide insight on their final thoughts of olaratumab and the future of soft tissue sarcoma care.
Misty
April 18, 2017, 5:53pm
13
I started Olaratumab (Lartruvo) in the beginning of March. My side effects have been next to nothing. I am tired and get a slight headache on days 3 and 4 of my chemo cycles. I have been taking Doxorubicin, but have almost reached my limit. I will have my scans on May 2 to see if the Lartruvo has been helping. So far, I have been very happy with the Lartruvo.
Thanks for sharing Misty!
1 Like